By Cameron Chai
Dr. Anil R. Diwan, NanoViricides’ President and Chief Executive Officer, will deliver a presentation at the 10th Annual NanoBusiness Conference/NanoManufacturing Summit being conducted at the Seaport World Trade Center located in Boston, Massachusetts.
In his presentation, Dr. Diwan will elaborate on the company’s nanoviricides platform technology, its drugs under development, its successful completion of animal studies for FluCide, a therapeutic for influenza, and FluCide’s initial FDA submission.
NanoViricides has taken efforts to enable current good manufacturing practices (cGMP) capability for manufacturing its drug candidates, which will be needed during the filing of an application for investigational new drug to the FDA. The company has recently declared its proposal to lease an acquired space for its new cGMP production pilot facility and laboratory in Connecticut.
NanoViricides has selected NV-INF-1 as a clinical candidate for FluCide, its anti-influenza drug program, to develop for regulatory applications both locally and internationally. Based on the findings of the animal studies, the company expects that a single course therapy, which can be managed easily by a medical office and does not require follow-on treatment in most of the occasions, is possible for out-patients.
NanoViricides has also achieved success in HIVCide, its anti-HIV drug program. During the recently conducted SCID-hu Thy/Liv mouse model study, the program’s best drug candidate demonstrated effectiveness against HIV-1 equivalent to a three-drug highly active anti-retroviral therapy cocktail but at a minimal total dosage. The drug candidate was able to repress HIV viral load for a period of at least 28 days further than the last drug administration. These results as well as earlier successes in anti-HIV drug development prove that HIVCide can be used as a ‘functional cure’ for HIV/AIDS either individually or in combination with other medicines.